Trial Profile
Efficacy of Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy in Patients With Viral Suppression. Randomized, Open-label 96 Weeks Non-inferiority Trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2018
Price :
$35
*
At a glance
- Drugs Atazanavir/ritonavir (Primary) ; Lamivudine; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SALT
- 11 Jun 2018 Results of sub-study published in the Journal of Antimicrobial Chemotherapy.
- 13 Sep 2016 Non-inferiority, 96 weeks follow-up analysis (n=286) published in the Journal of Antimicrobial Chemotherapy.
- 25 Feb 2016 Results of sub-study of 96 weeks (n=92) presented at the 23rd Conference on Retroviruses and Opportunistic Infections